Main Menu
MSAA
  • Toll-Free Helpline Call Us Toll Free (800) 532-7667 Search
  • Get MS Updates
  • Información en Español
  • Donate
  • Skip main navigation
MSAA logo
  • MS Information
    • MS Overview & Glossary
    • Newly Diagnosed
    • Symptoms
    • Treatments
    • COVID-19 and MS
    • Prescription Assistance Programs
    • Clinical Trials Search
    • Publications
    • Latest News from MSAA
    • MSi Videos
    • Podcasts from MSAA
    • Toll-free Helpline & Chat
    • Información en Español
    • MS FAQs
  • How MSAA Can Help
    • Toll-free Helpline & Chat
    • Publications
    • MSi Videos
    • Cooling Products
    • Equipment Products
    • MRI Access Program
    • Educational Programs
    • Shared-Management Tools
    • Overall Wellness
    • Online Aquatic Center
    • FAQs
  • Living with MS
    • My MSAA Community
    • MS Conversations Blog
    • My MS Journey
    • My MS Manager™ Mobile App
    • MS Relapse Resource Center
    • My Health Insurance Guide
    • My MS Resource Locator
    • Overall Wellness
    • Online Aquatic Center
    • Educational Programs
  • Donate
    • Make A Donation
    • Honor and Memorial Donations
    • Become a Monthly Improver
    • Planned Giving
    • Other Ways to Give
      • Donor-Advised Funds
      • Vehicle Donation
      • Matching Gifts
      • Shop & Support MSAA
    • Donation FAQs
  • Get Involved
    • Special Events
    • Art Showcase
    • Do-It-Yourself Fundraiser
    • Partnerships
    • Volunteer With MSAA
    • FAQ
  • Calendar
  • About MSAA
    • Mission and Overview
    • MSAA’s 50th Anniversary
    • MS Awareness Month
    • MSAA Achievements
    • Contact Us
    • Board of Directors
    • Healthcare Advisory Council
    • African American Advisory Board
    • Hispanic/Latinx Advisory Board
    • MSAA Strategic Plan
    • Navigating MS
    • MS Coalition
    • Annual Report
    • Financial Information
  • Search
  • Home
  • Copaxone®
Back to Treatment Guide

Copaxone®

glatiramer acetate

Quick Facts

Copaxone® favors Th2 cells which quiet inflammation and help block T cells that damage myelin in the central nervous system.

Self-injected under the skin

Daily or three times per week, depending on dosage

Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS

Potential Benefit:

In clinical trials, Copaxone® was compared to placebo and showed:

  • Approximately 29% fewer relapses
  • 35-40% reduction in new and enlarging T2 lesions
  • 40-45% reduction in gadolinium-enhancing T1 lesions

Disability progression over 10 years was stable or improved.

 

Common Potential Side Effects

Nausea, injection site reactions. lipoatrophy (injection site indentations in the skin).

Prescription Assistance:

Shared Solutions >

For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.

Hear from the Expert
Andrew H. Woo, MD, PhD
Assistant Clinical Professor of Neurology
David Geffen School of Medicine at UCLA, Santa Monica Neurological Consultants
Andrew H. Woo, MD, PhD
“I like to align with patients, engage them, and activate them with a plan.”

DRUGMAKER

Teva

HOW Copaxone® WORKS

Copaxone® (glatiramer acetate) is a synthetic protein that chemically resembles a protein found in myelin. Copaxone modifies immune processes that favor Th2 cells that quiet inflammation and blocks T cells that damage myelin in the central nervous system.

FDA-Approved

Copaxone® was FDA-approved in 1996. It is approved to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease, in adults.

Potential Side Effects

Injection-site skin reaction and occasional systemic reaction. This occurs at least once in about 10% of people tested. Possible reactions occur about 5-15 minutes after injection. Symptoms may include anxiety, dizziness, depression, flushing, palpitations, chest tightness, shortness of breath. Symptoms are typically short lived, do not affect your health and do not require specific intervention.

OTHER KEY INFORMATION

No testing is required before or while taking Copaxone®

This treatment is also available in generic form under the brand name Glatopa (developed by Sandoz) and as Generic Glatiramer Acetate (developed by Viatris). These generic options are administered in the same way and in the same dosage as Copaxone.

Patient advocates talk about
their treatment experience

  • Kristie Salerno Kent
    MS Advocate, Patient Advocacy Consultant
    Kristie Salerno Kent
    “I have had situations where treatments aren’t approved at first. My doctors, nurses, they actually go to bat for me and made it happen.”
  • Azure Antoinette
    MS Advocate
    Azure Antoinette
    "I will be undergoing my first disease-modifying therapy to help treat multiple sclerosis in my body and while I’m very nervous, I am equally as excited and looking forward to the positive effects of how I will feel physically, and mentally, and emotionally."
  • Damian Washington
    MS Advocate
    Damian Washington
    “Nobody’s going to be looking out for your best interests better than you.”
  • Cathy Chester
    MS Advocate
    Cathy Chester
    “I think it’s really important to talk about how to age with this illness.”
  • Lauren Hutton-Work
    MS Advocate
    Lauren Hutton-Work
    “Just because you have this disease does not mean that your work life should be awkward or uncomfortable.”
  • Chernise Joseph
    MS Advocate
    Chernise Joseph
    “My first neurologist was a frontline neurologist, he wasn’t an MS specialist.”
  • Julian Gamboa
    MS Advocate
    Julian Gamboa
    “If you’re newly diagnosed with multiple sclerosis remember it’s always okay to get a second opinion.”
  • Lauren and Sam Alcorn
    MS Advocates
    Lauren and Sam Alcorn
    “Our future is uncertain and we have to enjoy each other and love each other in the present.”
  • Shawn Feliciano
    MS Advocate
    Shawn Feliciano
    “I want to know what medications might work best for someone who’s Hispanic.”
  • Darlene Feigen
    MS Advocate
    Darlene Feigen
    “The sooner you get on a therapy the better it is in the long run.”
  • Birgit Bauer
    MS Advocate
    Birgit Bauer
    “At the end of the appointment you should have an answer to the most important questions.”
  • Ellen Tutton
    MS Advocate
    Ellen Tutton
    “I looked up all the different disease-modifying therapies and compared them to my lifestyle.”
  • Victoria Marie Reese
    MS Advocate
    Victoria Marie Reese
    “I’m trying to show my daughter that taking care of yourself is cool.”
    • MSAA logo
    • (800) 532-7667
    • msaa@mymsaa.org
    • MSAA is a 501(C)(3) nonprofit registered in the US under EIN: 22-1912812.Copyright ©2023 Multiple Sclerosis Association of America.Reproduction of material from any mymsaa.org pages without written permission is strictly prohibited.
    • GET EMAIL UPDATES
    • Privacy Policy and Terms of Use
    • Donor Privacy Policy
    • Financial Information
    • Información en Español
    • Contact Us
    • HONCODE
    • Guidestar Logo
    • America's Charities
    • Facebook
    • Twitter
    • Instagram
    • Tik Tok
    • Pinterest
    • YouTube
    • LinkedIn
    • ESSENTIAL
    • Accessibility Statement

Last modified: Aug 12, 2022

×